Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) reported positive results from a second Phase 3 trial of plecanatide to treat irritable bowel syndrome with constipation sending the stock price soaring $1.03 to close at $5.77.
Positive trial results for Synergy Pharmaceuticals
December 23, 2016 at 17:08 PM EST
